» Articles » PMID: 16691623

Influence of Local Recurrence on Survival in Patients with Extremity Osteosarcoma Treated with Neoadjuvant Chemotherapy: the Experience of a Single Institution with 44 Patients

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2006 May 13
PMID 16691623
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Risk factors for local recurrence (LR) after osteosarcoma, such as surgical margins and histologic response to preoperative treatment, have been well documented, whereas the outcome for patients who locally recur has not been well established yet.

Methods: Retrospective analysis of the management and outcome of 44 patients who developed LR after treatment of osteosarcoma of the extremities with neoadjuvant chemotherapy was performed in a single institution between 1983 and 1999.

Results: In 24 patients (54.5%), LR was the first sign of recurrence; in 8 patients (18.2%) LR followed systemic recurrence and in 12 patients (27.3%), the 2 events, local and systemic recurrence, were concurrent. Of the 44 patients, 26 with local recurrences were free of disease, but only 5 were long-term event-free survivors, and 39 patients developed further recurrences: 37 died of the tumor and 2 were alive with uncontrolled disease at the time of last follow-up. The 5-year disease-free survival rate after the last recurrence was 15.9%; it was 25.9% for patients who achieved remission and 0% for the others. The only prognostic factor identified for post-LR disease-free survival was the presence of systemic recurrence at the time of diagnosis of LR or before (5-year postrecurrence event-free survival rate of 29.1% for patients without metastases at the time of local recurrence vs. 0% for those with metastases; P = .02).

Conclusions: These results confirm that patients with osteosarcoma of the extremities who develop LR are at a very significantly high risk of developing metastatic disease and dying of the tumor.

Citing Articles

Clinical value of ultrasound for the evaluation of local recurrence of primary bone tumors.

Wang Y, Yu P, Liu F, Wang Y, Zhu J Front Oncol. 2022; 12:902317.

PMID: 36185277 PMC: 9520522. DOI: 10.3389/fonc.2022.902317.


An overview of resistance to chemotherapy in osteosarcoma and future perspectives.

Garcia-Ortega D, Cabrera-Nieto S, Caro-Sanchez H, Cruz-Ramos M Cancer Drug Resist. 2022; 5(3):762-793.

PMID: 36176756 PMC: 9511812. DOI: 10.20517/cdr.2022.18.


International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Abib S, Chui C, Cox S, Abdelhafeez A, Fernandez-Pineda I, Elgendy A Ecancermedicalscience. 2022; 16:1356.

PMID: 35510137 PMC: 9023308. DOI: 10.3332/ecancer.2022.1356.


Compressive osseointegration for endoprosthetic reconstruction.

Parlee L, Kagan R, Doung Y, Hayden J, Gundle K Orthop Rev (Pavia). 2020; 12(3):8646.

PMID: 33312488 PMC: 7726822. DOI: 10.4081/or.2020.8646.


Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group.

Nakamura T, Sugaya J, Naka N, Kobayashi H, Okuma T, Kunisada T Cancer Manag Res. 2020; 12:10017-10022.

PMID: 33116858 PMC: 7567545. DOI: 10.2147/CMAR.S270178.